Dermatology Program Kicks Off ACAAI 2021 Annual Scientific Meeting

Sessions with a laser focus on dermatologic issues ranging from new JAK inhibitors to disparities in atopic dermatitis anchor the opening day of the 2021 American College of Allergy, Asthma & Immunology (ACAAI) annual scientific meeting.

The American College of Allergy, Asthma & Immunology (ACAAI) becomes the first major allergy meeting to reconvene live since the beginning of the pandemic with the opening of its 2021 annual scientific meeting held November 4 to 8 in New Orleans, Louisiana. 

Experts in the fields of allergy/immunology, dermatology, pulmonology, and otolaryngology highlight the conference’s signature Podium to Practice focus across a broad range of presentations for the in-person and live streamed program.

This year’s theme, Promoting Innovation and Diversity, provides a framework for the plenary sessions, daily presentations, and hands-on workshops. 

Follow along as Dermatology Times® reports on the breakthroughs and best practices being showcased during this 5-day meeting. The 2021 program begins today with a full day focus on the latest news in dermatology. 

Speakers drill down on the hottest topics in the specialty:

  • New topicals, JAK inhibitors, and biologics and their impact on treatment regimens for atopic dermatitis (AD)
  • Shared decision making in managing moderate to severe AD
  • Disparities in AD, from differences by age group to the similarities, differences, and gaps in knowledge among patients of various ethnicities who develop AD
  • Improvements in allergy testing and diagnostics
  • The lingering shadow of COVID-19 and the innovations that will address this
  • Allergens’ expanding impact on skin

Other highlights of ACAAI’s 2021 annual meeting include a new version of the popular 7 for 11 series covering hot topics in dermatology, the effect of climate change on allergies, a pediatric update, and an expanded programming on practice management for both practice managers and their teams. For a full agenda, click here